SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of abiraterone acetate therapy presented at the 2014 ASCO Genitourinary Cancers Symposium. Karim Fizazi MD PhD, Professor of Medicine and Head of the Department of Cancer Medicine at the Institut Gustave Roussy in Villejuif, Paris, discussed his group’s findings and the implications for using new generation androgen deprivation therapy in the advanced stages of prostate cancer.
Dr. Karim Fizazi MD PhD
Head of the Department of Cancer Medicine
Institut Gustave Roussy, Villejuif, Paris
Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.
Web link: http://meetinglibrary.asco.org/content/123754-142
Gleason score, abiraterone, metastatic castration-resistant prostate cancer, ASCO GU 2014 Symposium San Francisco, anti-androgen therapy, androgen deprivation,